Overview
An Investigational Drug Study to Assess Weight Loss in Patients With Type 2 Diabetes Mellitus (0364-011)(TERMINATED)
Status:
Terminated
Terminated
Trial end date:
2008-11-01
2008-11-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
A worldwide study with extension in patients with type 2 diabetes mellitus to assess the safety and tolerability as well as the effects of treatment with an investigational drug for weight loss on body weight.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Merck Sharp & Dohme Corp.Treatments:
N-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide
Criteria
Inclusion Criteria:- Body Mass Index (BMI) between 27 kg/m2 and 43 kg/m2 and HbA1c between 7.0% and 10%
Exclusion Criteria:
- History of major psychiatric disorder
- Blood pressure greater than 160/100
- Use of any antihyperglycemic agent other than metformin
- Triglycerides greater then 600 mg/dL